 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...190191192193194195196197198199200...203204» |
- Enrollment open, Trial initiation date, Surgery: Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 8, 2015
P4, N=660, Recruiting, Sponsor: Centre Hospitalier Universitaire de Québec, CHU de Québec
Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jul 2015
- | Humira (adalimumab) / AbbVie
Biomarker, New P4 trial: Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) ? Agent's Efficacy in Ankylosing Spondylitis Patients (clinicaltrials.gov) - Jul 8, 2015
P4, N=70, Recruiting, Sponsor: Universidade Nova de Lisboa
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
New P4 trial: Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study (clinicaltrials.gov) - Jul 6, 2015
P4, N=30, Recruiting, Sponsor: Chung Shan Medical University
- | Tremfya (guselkumab) / J&J
Enrollment closed: VOYAGE 1: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Jul 6, 2015
P3, N=833, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jul 2015 Recruiting --> Active, not recruiting
- |||| clazakizumab (CSL300) / CSL Behring
Trial completion, P2b data: Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate (clinicaltrials.gov) - Jun 30, 2015
P2b, N=418, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Jun 24, 2015
P3, N=400, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Jun 20, 2015
P3, N=400, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Jan 2016
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P2 trial: Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA) (clinicaltrials.gov) - Jun 15, 2015
P2, N=130, Recruiting, Sponsor: Canadian Research & Education in Arthritis
- ||| Adalimumab BS MA (adalimumab biosimilar) / Mochida, LG Chem
Trial completion: Pharmacokinetics and Safety Study of LBAL in Healthy Subjects (clinicaltrials.gov) - Jun 15, 2015
P1, N=116, Completed, Sponsor: LG Life Sciences
Trial primary completion date: Mar 2015 --> Jan 2016 Not yet recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: VIP-Et: Vascular Inflammation in Psoriasis - Extension Study (clinicaltrials.gov) - Jun 12, 2015
P4, N=96, Active, not recruiting, Sponsor: University of Pennsylvania
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- Humira (adalimumab) / AbbVie
Enrollment closed: Vascular Inflammation in Psoriasis Trial (The VIP Trial) (clinicaltrials.gov) - Jun 12, 2015
P4, N=96, Active, not recruiting, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=75, Recruiting, Sponsor: University Hospital, Ghent
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Dec 2015
- Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Clinical Trial Using Humira in Netherton Syndrome (clinicaltrials.gov) - Jun 11, 2015
P2, N=23, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Jun 2014 --> Dec 2015 Trial primary completion date: Jan 2016 --> Jun 2016
- | Humira (adalimumab) / AbbVie
Trial primary completion date: Efficacy of Humira in Behcet Patients With Arthritis (clinicaltrials.gov) - Jun 11, 2015
P3, N=15, Recruiting, Sponsor: Rambam Health Care Campus
Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Sep 2015 --> Sep 2016
- Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI (clinicaltrials.gov) - Jun 6, 2015
P2/3, N=4, Recruiting, Sponsor: Los Angeles Biomedical Research Institute
Trial primary completion date: Sep 2015 --> Sep 2016 Not yet recruiting --> Recruiting
- |||| Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: ORBIT: Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy (clinicaltrials.gov) - May 29, 2015
P4, N=302, Completed, Sponsor: University of Glasgow
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
New P2 trial: Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis (clinicaltrials.gov) - May 28, 2015
P2, N=300, Recruiting, Sponsor: Chung Shan Medical University
- Orencia (abatacept) / BMS, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. (clinicaltrials.gov) - May 28, 2015
P4, N=477, Active, not recruiting, Sponsor: Julia Brown
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
New trial: An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY) (clinicaltrials.gov) - May 22, 2015
P=N/A, N=190, Not yet recruiting, Sponsor: AbbVie
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA (clinicaltrials.gov) - May 22, 2015
P4, N=200, Not yet recruiting, Sponsor: University of Illinois at Chicago
- Humira (adalimumab) / Eisai, AbbVie
New trial, PK/PD data: Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study (clinicaltrials.gov) - May 21, 2015
P=N/A, N=30, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Trial initiation date, Trial primary completion date: Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial (clinicaltrials.gov) - May 20, 2015
P4, N=80, Recruiting, Sponsor: Schneider Children's Medical Center, Israel
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> May 2015 | Trial primary completion date: May 2018 --> Nov 2018
- ||||| Plivensia (sirukumab) / J&J
Enrollment closed, Monotherapy: SIRROUND-H: A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA (clinicaltrials.gov) - May 19, 2015
P3, N=559, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> May 2015 | Trial primary completion date: May 2018 --> Nov 2018 Recruiting --> Active, not recruiting
- | Humira (adalimumab) / AbbVie
Enrollment open, Trial initiation date, Trial primary completion date: The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients (clinicaltrials.gov) - May 8, 2015
P3, N=30, Recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Oct 2014 | Trial primary completion date: Mar 2015 --> Oct 2015
- Humira (adalimumab) / Eisai, AbbVie
New P2/3 trial: Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI (clinicaltrials.gov) - May 7, 2015
P2/3, N=4, Not yet recruiting, Sponsor: Los Angeles Biomedical Research Institute
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (clinicaltrials.gov) - May 6, 2015
P3, N=200, Active, not recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Oct 2014 | Trial primary completion date: Mar 2015 --> Oct 2015 Recruiting --> Active, not recruiting
- ||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
New trial, Observational data: Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients (clinicaltrials.gov) - May 5, 2015
P=N/A, N=110, Recruiting, Sponsor: University of Wisconsin, Madison
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: RAPIDAt: Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease (clinicaltrials.gov) - May 1, 2015
P4, N=98, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2015 --> Jan 2016
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, HEOR: Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment) (clinicaltrials.gov) - May 1, 2015
P=N/A, N=2000, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Aug 2015 --> Jan 2016 Trial primary completion date: Apr 2015 --> Sep 2015
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation) (clinicaltrials.gov) - May 1, 2015
P=N/A, N=100, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Apr 2015 --> Sep 2015 Trial primary completion date: Sep 2015 --> Jun 2017
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: LOTOS: Documentation of Humira in Psoriasis Patients in Routine Clinical Practice (clinicaltrials.gov) - May 1, 2015
P=N/A, N=3000, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Sep 2015 --> Jun 2017 Trial primary completion date: Nov 2018 --> Oct 2016
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, HEOR: AGIL: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 1, 2015
P=N/A, N=4500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Nov 2018 --> Oct 2016 Trial primary completion date: Dec 2018 --> May 2017
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - May 1, 2015
P=N/A, N=80, Recruiting, Sponsor: AbbVie
Trial primary completion date: Dec 2018 --> May 2017 N=140 --> 80
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (clinicaltrials.gov) - Apr 22, 2015
P3, N=200, Recruiting, Sponsor: AbbVie
N=140 --> 80 Trial primary completion date: Feb 2015 --> Feb 2016
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: ORIENT: Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA (clinicaltrials.gov) - Apr 21, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: AbbVie
Trial primary completion date: Feb 2015 --> Feb 2016 Initiation date: Mar 2015 --> Jun 2015
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities (clinicaltrials.gov) - Apr 21, 2015
P=N/A, N=288, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Mar 2015 --> Jun 2015 N=203 --> 288
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change, Trial primary completion date, Immunomodulating: Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab. (clinicaltrials.gov) - Apr 20, 2015
P=N/A, N=17, Completed, Sponsor: University of North Carolina, Chapel Hill
N=203 --> 288 Active, not recruiting --> Completed | N=52 --> 17 | Trial primary completion date: Mar 2014 --> Mar 2015
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis (clinicaltrials.gov) - Apr 19, 2015
P4, N=106, Active, not recruiting, Sponsor: Innovaderm Research Inc.
Active, not recruiting --> Completed | N=52 --> 17 | Trial primary completion date: Mar 2014 --> Mar 2015 Trial primary completion date: Nov 2014 --> Nov 2015
- || Humira (adalimumab) / AbbVie
Trial primary completion date: Adalimumab-psoriasis and Small Bowel Lesions (clinicaltrials.gov) - Apr 19, 2015
P4, N=100, Recruiting, Sponsor: Innovaderm Research Inc.
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Nov 2014 --> Nov 2015
- Trial primary completion date: Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity (clinicaltrials.gov) - Apr 15, 2015
P=N/A, N=398, Recruiting, Sponsor: University Hospital, Montpellier
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Jun 2016 --> Jun 2017
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
New trial, Immunomodulating: Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator (clinicaltrials.gov) - Apr 9, 2015
P=N/A, N=20, Not yet recruiting, Sponsor: Indiana University
- Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Trial primary completion date: Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) (clinicaltrials.gov) - Apr 9, 2015
P4, N=110, Active, not recruiting, Sponsor: University Hospital, Tours
Trial primary completion date: Jun 2016 --> Jun 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Apr 2015
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: VISUAL III: A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis (clinicaltrials.gov) - Apr 9, 2015
P3, N=400, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Apr 2015 Enrolling by invitation --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, HEOR: Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life (clinicaltrials.gov) - Apr 9, 2015
P=N/A, N=198, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Visual II: Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis (clinicaltrials.gov) - Apr 9, 2015
P3, N=261, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Humira (adalimumab) / AbbVie
Trial completion, HEOR: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (clinicaltrials.gov) - Apr 9, 2015
P3, N=463, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Trial completion: T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade (clinicaltrials.gov) - Mar 24, 2015
P=N/A, N=52, Completed, Sponsor: Imperial College London
Active, not recruiting --> Completed Recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change: ADACAL: Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants (clinicaltrials.gov) - Mar 17, 2015
P3, N=15, Terminated, Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Recruiting --> Completed N=160 --> 15
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: APPRECIA: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (clinicaltrials.gov) - Mar 17, 2015
P3, N=86, Completed, Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
N=160 --> 15 Active, not recruiting --> Completed
- Enrollment change: ABI-RA: Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=700, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed N=500 --> 700